ASCO: 2023 | EHA and ASCO 2023 highlights: promising treatments in AML, MDS, and ALL
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares her highlights from the 2023 EHA and ASCO conferences. From EHA, Dr Wang discusses highlights for the treatment of acute myeloid leukemia (AML) such as research into menin inhibitors as well as the MORPHO study (NCT02997202) of gilteritinib, a FLT3 inhibitor, as a maintenance therapy following allogeneic stem cell transplantation (alloSCT). From ASCO, Dr Wang covers promising results for using CAR-T therapy in acute lymphoblastic leukemia (ALL), and speaks on the positive results of Phase III trials investigating luspatercept and imetelstat for low-risk myelodysplastic syndromes (MDS).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
